C79.89

Secondary malignant neoplasm of other specified sites

C79.89 is a clinical classification for secondary malignant neoplasms (metastases) occurring in anatomical locations that are specifically identified but do not have a more specific unique code within the C79.x series. While common sites like the lungs (C78.0), liver (C78.7), and bones (C79.5) have dedicated codes, C79.89 is utilized for metastatic spread to sites such as the heart, pericardium, skeletal muscle, skin, or certain endocrine glands when the involvement is secondary to a primary tumor elsewhere. This code signifies advanced, Stage IV oncological disease where the primary cancer has disseminated through hematogenous, lymphatic, or transcoelomic pathways. Management typically focuses on systemic therapy and palliative intervention rather than curative resection of the secondary site alone.

Clinical Symptoms

  • Localized pain or tenderness at the site of metastasis
  • Palpable subcutaneous or intramuscular nodules
  • Unexplained weight loss and cachexia
  • Persistent fatigue and malaise
  • Night sweats
  • Site-specific dysfunction (e.g., cardiac arrhythmias if heart is involved)
  • Localized swelling or edema
  • Pathological fractures if cortical bone adjacent to muscle is involved
  • Anemia of chronic disease
  • Paraneoplastic syndromes

Common Causes

  • Dissemination from primary breast adenocarcinoma
  • Metastatic spread from primary lung carcinoma (small cell or non-small cell)
  • Metastatic cutaneous or mucosal melanoma
  • Advanced renal cell carcinoma
  • Gastrointestinal tract malignancies (colorectal, gastric, pancreatic)
  • Malignant cell migration via blood vessels (hematogenous spread)
  • Lymphatic vessel invasion and transit
  • Direct seeding within body cavities (transcoelomic spread)
  • Aggressive tumor biology and high histological grade
  • Failure of primary tumor immunosurveillance

Documentation & Coding Tips

Identify and document the specific anatomical site of the secondary malignancy beyond the general category of other specified sites to justify the code selection.

Example: Patient with known primary infiltrating ductal carcinoma of the right breast presents with a new biopsy-confirmed secondary malignant neoplasm of the skin of the right temple. Lesion is active and currently being treated with localized radiation therapy. Patient also has associated secondary lymphedema of the right upper extremity.

Billing Focus: Documentation identifies the specific site (skin of temple) and laterality (right) to support the use of C79.89 alongside the primary malignancy code.

Distinguish between an active secondary malignancy and a history of malignancy to ensure accurate ICD-10 coding and risk adjustment.

Example: Evaluation of metastatic site in the left adrenal gland, secondary to primary lung adenocarcinoma. The adrenal lesion is enlarging on CT and requires a change in systemic therapy protocol. Current treatment includes pembrolizumab.

Billing Focus: Clearly distinguishes the adrenal site as an active metastatic focus, requiring the use of C79.89 rather than a history-of code.

Clearly link the secondary malignancy to its primary origin or state that the primary site is unknown if applicable.

Example: Metastatic squamous cell carcinoma found in the skeletal muscle of the right thigh. Extensive workup has failed to identify the primary site. The thigh lesion is the primary focus of current palliative intervention.

Billing Focus: Documentation of the site as skeletal muscle justifies C79.89, and the notation of unknown primary directs the use of C80.1.

Document clinical complications resulting from the secondary neoplasm, such as obstruction, hemorrhage, or localized pain syndromes.

Example: Patient with secondary malignancy of the peritoneum causing malignant ascites and bowel obstruction. Management requires therapeutic paracentesis and surgical consultation for venting gastrostomy tube.

Billing Focus: Lists complications (ascites, obstruction) that allow for the coding of additional diagnoses, increasing the overall encounter complexity.

Specify the treatment plan for the secondary site, whether it is surgical excision, radiation, chemotherapy, or palliative care.

Example: Metastatic melanoma to the right parotid gland. Planned intervention involves surgical resection followed by adjuvant immunotherapy. Patient is currently experiencing grade 2 fatigue and mild xerostomia due to ongoing treatments.

Billing Focus: Linking the treatment plan to the specific metastatic site supports the medical necessity of the procedure and associated E/M services.

Relevant CPT Codes

Related Diagnoses

Hierarchy